Titan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan Corporation
Titan Pharmaceuticals (NASDAQ:BTTC) announced the closing of its merger with Black Titan Corporation and TalenTec Sdn. Bhd., effective October 1, 2025. Under the August 19, 2024 agreement, Titan became a wholly owned subsidiary of Black Titan and each issued Titan share converted one-for-one into Black Titan ordinary shares. Trading of Titan common stock ceased on October 1, 2025, and Black Titan ordinary shares began trading on Nasdaq under the ticker BTTC on October 2, 2025. ARC Group Ltd. served as exclusive financial advisor to Black Titan. The release includes standard forward-looking statements and SEC filing references.
Titan Pharmaceuticals (NASDAQ:BTTC) ha annunciato la chiusura della fusione con Black Titan Corporation e TalenTec Sdn. Bhd., effettiva 1 ottobre 2025. In base all'accordo del 19 agosto 2024, Titan è diventata una filiale interamente controllata di Black Titan e ogni azione Titan emessa si è convertita uno a uno in azioni ordinarie di Black Titan. La negoziazione delle azioni ordinarie Titan è cessata il 1 ottobre 2025, e le azioni ordinarie di Black Titan hanno iniziato a essere negoziate su Nasdaq con il ticker BTTC il 2 ottobre 2025. ARC Group Ltd. ha funto da consulente finanziario esclusivo per Black Titan. Il comunicato include dichiarazioni previsionali standard e riferimenti ai filing SEC.
Titan Pharmaceuticals (NASDAQ:BTTC) anunció el cierre de su fusión con Black Titan Corporation y TalenTec Sdn. Bhd., con efecto 1 de octubre de 2025. Según el acuerdo del 19 de agosto de 2024, Titan se convirtió en una subsidiaria de propiedad total de Black Titan y cada acción Titan emitida se convirtió una por una en acciones ordinarias de Black Titan. La negociación de las acciones comunes de Titan cesó el 1 de octubre de 2025, y las acciones ordinarias de Black Titan comenzaron a cotizar en Nasdaq bajo el ticker BTTC el 2 de octubre de 2025. ARC Group Ltd. actuó como asesor financiero exclusivo de Black Titan. El comunicado incluye declaraciones prospectivas estándar y referencias a presentaciones ante la SEC.
Titan Pharmaceuticals (NASDAQ:BTTC)은 Black Titan Corporation 및 TalenTec Sdn. Bhd.와의 합병을 2025년 10월 1일부로 종결했다고 발표했다. 2024년 8월 19일 합의에 따라 Titan은 Black Titan의 전액 출자 자회사가 되었고, Titan의 각 주식은 일대일로 Black Titan의 보통주로 전환되었다. Titan 보통주의 거래는 2025년 10월 1일에 중지되었고, Black Titan의 보통주는 BTTC라는 표기로 2025년 10월 2일부터 나스닥에서 거래를 시작했다. ARC Group Ltd.는 Black Titan의 독점 금융 고문으로 활동했다. 보도자료에는 일반적인 전망 진술 및 SEC 제출 참조가 포함되어 있다.
Titan Pharmaceuticals (NASDAQ:BTTC) a annoncé la clôture de sa fusion avec Black Titan Corporation et TalenTec Sdn. Bhd., effective le 1er octobre 2025. Selon l’accord du 19 août 2024, Titan est devenue une filiale détenue en totalité par Black Titan et chaque action Titan émise s’est convertie en une pour une en actions ordinaires de Black Titan. La négociation des actions ordinaires de Titan a cessé le 1er octobre 2025, et les actions ordinaires de Black Titan ont commencé à être négociées sur Nasdaq sous le ticker BTTC le 2 octobre 2025. ARC Group Ltd. a agi en tant que conseiller financier exclusif de Black Titan. Le communiqué contient des déclarations prospectives standard et des références de dépôt SEC.
Titan Pharmaceuticals (NASDAQ:BTTC) gab den Abschluss seiner Fusion mit Black Titan Corporation und TalenTec Sdn. Bhd. bekannt, wirksam zum 1. Oktober 2025. Gemäß der Vereinbarung vom 19. August 2024 wurde Titan eine vollständig beherrschte Tochtergesellschaft von Black Titan, und jede ausgegebene Titan-Aktie wurde eins zu eins in Black Titan-Ordentliche Aktien umgewandelt. Der Handel mit Titan-Stammaktien wurde am 1. Oktober 2025 eingestellt, und Black Titan-Ordentlichaktien begannen am 2. Oktober 2025 unter dem Kürzel BTTC an der Nasdaq zu gehandelt. ARC Group Ltd. fungierte als exklusiver Finanzberater von Black Titan. Die Pressemitteilung enthält standardmäßige zukunftsgerichtete Aussagen und Verweise auf SEC-Unterlagen.
Titan Pharmaceuticals (NASDAQ:BTTC) أعلنت عن إغلاق اندماجها مع Black Titan Corporation و TalenTec Sdn. Bhd.، ساري المفعول اعتباراً من 1 أكتوبر 2025. وفقاً للاتفاق الموقع في 19 أغسطس 2024، أصبحت Titan شركة فرعية مملوكة بالكامل لـ Black Titan وكل سهم Titan مُصدر تم تحويله واحد مقابل واحد إلى أسهم عادية لـ Black Titan. توقّف تداول أسهم Titan العادية في 1 أكتوبر 2025، وبدأت أسهم Black Titan العادية التداول في ناسداك تحت الرمز BTTC في 2 أكتوبر 2025. ARC Group Ltd. عملت كمستشار مالي حصري لـ Black Titan. البيان يتضمن عبارات توضيحية/تطلعية محددة وإشارات إلى ملفات SEC.
Titan Pharmaceuticals (NASDAQ:BTTC) 宣布完成与 Black Titan Corporation 及 TalenTec Sdn. Bhd. 的合并，生效日期为 2025年10月1日。根据2024年8月19日的协议，Titan 成为 Black Titan 的全资子公司， Titan 发行的每股将 一对一地转换为 Black Titan 的普通股。Titan 普通股的交易在 2025年10月1日 停止，Black Titan 的普通股在 2025年10月2日 起在纳斯达克以代码 BTTC 交易。ARC Group Ltd. 担任 Black Titan 的独家金融顾问。公告包含标准前瞻性陈述及对 SEC 文件的引用。
- Black Titan ordinary shares listed on Nasdaq under BTTC on Oct 2, 2025
- Titan converted into a wholly owned subsidiary effective Oct 1, 2025
- Share conversion executed at a one-for-one ratio
- Trading of Titan common stock ceased at close on Oct 1, 2025, shifting liquidity
- Titan shareholders no longer hold Titan common stock post-merger
Insights
Merger closed; Black Titan now the parent and ordinary shares trade as NASDAQ: BTTC.
What it means: The Merger and Contribution and Share Exchange Agreement dated August 19, 2024 completed with Titan becoming a wholly owned subsidiary of Black Titan Corporation effective October 1, 2025, and Titan shares converted one-for-one into Black Titan ordinary shares.
Why it matters: A completed legal and listing transition changes corporate control, share identity, and investor reporting lines; trading ceased for Titan on the Nasdaq Capital Market at close of business October 1, 2025 and Black Titan ordinary shares began trading on Nasdaq on October 2, 2025, which is the concrete market-access outcome disclosed.
Monitor the October 1–2, 2025 conversion and trading dates for any subsequent SEC filings that disclose pro forma capitalization, governance, or financial statement restatements.
NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (“Titan” or “TTNP”) today announced the successful closing of its previously announced merger with Black Titan Corporation (“Black Titan”) and TalenTec Sdn. Bhd. (“TalenTec”). Following the merger, the combined company's ordinary shares,
Pursuant to the Merger and Contribution and Share Exchange Agreement dated August 19, 2024, Titan has become a wholly owned subsidiary of Black Titan Corporation, effective as of October 1, 2025.
As part of the transaction, each issued and outstanding share of Titan common stock was automatically converted into ordinary shares of Black Titan on a one-for-one basis. Trading of Titan’s common stock on the Nasdaq Capital Market ceased trading at the close of business on October 1, 2025, and Black Titan’s ordinary shares commenced trading on Nasdaq on October 2, 2025.
Chay W. J., CEO of Black Titan, remarked, “This merger represents more than a structural change, it’s the beginning of a new chapter of innovation and global expansion. We are well-positioned to execute our strategic vision and bring transformative value to our stakeholders.”
ARC Group Ltd. acted as the exclusive financial advisor to Black Titan Corporation in connection with the transaction.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, which may cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, those described in the filings of Black Titan Corporation and Titan Pharmaceuticals, Inc. with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Neither company undertakes any obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this release.
Media & Investor Contacts:
Chay W. J.
Chief Executive Officer
(786) 769-7512
FAQ
When did the Titan and Black Titan merger become effective for BTTC?
What ticker will the combined company trade under and when did trading start?
How were Titan shares converted in the merger with Black Titan (BTTC)?
Did Titan common stock remain listed after the merger closing on Oct 1, 2025?
Who advised Black Titan on the merger transaction announced Oct 3, 2025?
